Evidence Hub

Antimicrobial susceptibility of Clostridioides difficile. An Argentinian multicenter study of isolates from human patients

R. Rollet, D. Vaustat, M. Litterio, L. Castello, L. Fernández-Canigia, C. Barberis, M. Legaria, Natalia Azula et al.

Revista Argentina de Microbiología, 2025

2 citations

Abstract

Clostridioides difficile is an etiological agent of diarrhea, and the use of antibiotics is one of the main risk factors for infection. Antimicrobials used for treatment are vancomycin (VAN), metronidazole (MET), and fidaxomicin. Resistant strains have been detected, exhibiting regional and institutional differences. The aim of this work was to determine the susceptibility profile of C. difficile clinical isolates to 14 antimicrobials, and to compare resistance among participating centers. A total of 208 consecutive isolates recovered from seven Argentinian hospitals between January 2018 and March 2020 were studied. MIC was determined by the agar dilution method (CLSI-M100 29ED). Azithromycin (AZM), clindamycin (CLI), ertapenem (ETP), imipenem (IMI), levofloxacin (LEV), linezolid (LNZ), meropenem (MER), metronidazole (MET), moxifloxacin (MOX), piperacillin-tazobactam (PTZ), rifaximin (RFX), teicoplanin (TEI), tigecycline (TGC), and VAN, were tested. The results were analyzed with SPSS 21.0. Chi-square was used to compare data, and statistical significance was set at p<0.05. Susceptibility percentages were as follows: VAN, TEI, and MET, 100%; TGC, 97.6%; PTZ, 96.2%; LNZ, 95.2%; MER, 99.5%; ETP, 60.9%; IMI, 42.8%; RFX, 55.6%; LEV, 48.6%; MOX, 46.1%; CLI, 29.9%; and azithromycin, 17.8%. Significant differences in resistance among centers were observed for: RFX (16.7%-91.7%), CLI (41.2%-86.1%), MOX (22.9%-97.2%), IMI (0%-55.6%), and azithromycin (62.5%-97.2%). Multidrug…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free